Evidence map›Paper›PMID 35086834›Full record

ReviewThe European respiratory journal2022

Allergen provocation tests in respiratory research: building on 50 years of experience.

Gail M Gauvreau, Beth E Davis, Guy Scadding, Louis-Philippe Boulet, Leif Bjermer, Adam Chaker, Donald W Cockcroft, Barbro Dahlén, Wyste Fokkens, Peter Hellings and 7 more

Open access · greenAbstract readReview
In one paragraph

Review in The European respiratory journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 29 citations in OpenAlex.

  1. Trial
  2. Recent advances in allergen immunotherapy.Chinese medical journal · 2026
    Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Respiratory Diseases Associated With Organic Dust Exposure.The journal of allergy and clinical immunology. In practice · 2024
    Review
  9. Review
  10. Article
  11. Efficacy Comparison of LPAInternational journal of molecular sciences · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 12 institutions in 7 countries.

Gail M GauvreauDept of Medicine, McMaster University, Hamilton, ON, Canada gauvreau@mcmaster.ca.
Beth E DavisDept of Medicine, University of Saskatchewan, Saskatoon, SK, Canada.
Guy ScaddingNational Heart and Lung Institute, Imperial College London, London, UK.
Louis-Philippe BouletInstitut Universitaire de Cardiologie et de Pneumologie de Québec, University of Laval, Laval, QC, Canada.
Leif BjermerDept of Clinical Sciences Lund, Respiratory Medicine and Allergology, Lund University, Lund, Sweden.
Adam ChakerTUM School of Medicine, Dept of Otolaryngology and Center of Allergy and Environment, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.
Donald W CockcroftDept of Medicine, University of Saskatchewan, Saskatoon, SK, Canada.
Barbro DahlénDept of Medicine, Huddinge Karolinska Institutet, Stockholm, Sweden.
Wyste FokkensDept of Otorhinolaryngology, Faculty of Medicine, University of Amsterdam, Amsterdam, The Netherlands.
Peter HellingsDept of Otorhinolaryngology, Faculty of Medicine, University of Amsterdam, Amsterdam, The Netherlands.
Nikolaos LazarinisDept of Medicine, Huddinge Karolinska Institutet, Stockholm, Sweden.
Paul M O'ByrneDept of Medicine, McMaster University, Hamilton, ON, Canada.ORCID 0000-0003-0979-281X
Ellen TufvessonDept of Clinical Sciences Lund, Respiratory Medicine and Allergology, Lund University, Lund, Sweden.ORCID 0000-0002-4941-332X
Santiago QuirceDept of Allergy, La Paz University Hospital, IdiPAZ and CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain.ORCID 0000-0001-8086-0921
Maurits Van MaarenDept of Allergology, Erasmus Medical Center, Rotterdam, The Netherlands.
Frans H de JonghFaculty of Engineering Technology, University of Twente, Enschede, The Netherlands.
Zuzana DiamantDept of Microbiology Immunology and Transplantation, KU Leuven, Leuven, Belgium.
Amsterdam University of Applied Sciences · NLKarolinska Institutet · SELund University · SEMcMaster University · CAUniversity of Saskatchewan · CACentro de Investigación Biomédica en Red de Enfermedades Respiratorias · ESErasmus MC · NLImperial College London · GBInstitut universitaire de cardiologie et de pneumologie de Québec · CATUM Klinikum · DEUniversity Medical Center Groningen · NLUniversity of Twente · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The allergen provocation test is an established model of allergic airway diseases, including asthma and allergic rhinitis, allowing the study of allergen-induced changes in respiratory physiology and inflammatory mechanisms in sensitised individuals as well as their associations. In the upper airways, allergen challenge is focused on the clinical and pathophysiological sequelae of the early allergic response, and is applied both as a diagnostic tool and in research settings. In contrast, bronchial allergen challenge has almost exclusively served as a research tool in specialised research settings with a focus on the late asthmatic response and the underlying type 2 inflammation. The allergen-induced late asthmatic response is also characterised by prolonged airway narrowing, increased nonspecific airway hyperresponsiveness and features of airway remodelling including the small airways, and hence allows the study of several key mechanisms and features of asthma. In line with these characteristics, allergen challenge has served as a valued tool to study the cross-talk of the upper and lower airways and in proof-of-mechanism studies of drug development. In recent years, several new insights into respiratory phenotypes and endotypes including the involvement of the upper and small airways, innovative biomarker sampling methods and detection techniques, refined lung function testing as well as targeted treatment options further shaped the applicability of the allergen provocation test in precision medicine. These topics, along with descriptions of subject populations and safety, in line with the updated Global Initiative for Asthma 2021 document, will be addressed in this review.

Indexed as

AsthmaRespiratory HypersensitivityAirway RemodelingAllergensBronchial Provocation TestsHumansAllergens

Identifiers

PMID35086834
PMCPMC9403392
OpenAlexW4210408887

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.